Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: RECEPTOR ; APOPTOSIS ; CELLS ; EXPRESSION ; INHIBITOR ; tumor ; COMBINATION ; Germany ; human ; IN-VIVO ; INHIBITION ; PATHWAYS ; PROTEIN ; DRUG ; RELEASE ; NF-KAPPA-B ; ACTIVATION ; LIGAND ; primary ; KERATINOCYTES ; ANTITUMOR-ACTIVITY ; MATURATION ; resistance ; CELL-DEATH ; INDUCED APOPTOSIS ; CYTOCHROME-C ; PRIMARY HUMAN KERATINOCYTES ; sensitization ; TRAIL ; DISC ; SIGNALING COMPLEX ; ANTICANCER DRUGS ; CD95 APO-1/FAS ; PROMOTES APOPTOSIS
    Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exerts potent cytotoxic activity against transformed keratinocytes, whereas primary keratinocytes are relatively resistant. In several cell types, inhibition of the proteasome sensitizes for TRAIL-induced apoptosis by interference with NF- kappaB activation. Here we describe a novel intracellular mechanism of TRAIL resistance in primary cells and how this resistance is removed by proteasome inhibitors independent of NF-kappaB in primary human keratinocytes. This sensitization was not mediated at the receptor-proximal level of TRAIL DISC formation or caspase 8 activation but further downstream. Activation of caspase 3 was critical, as it only occurred when mitochondrial apoptotic pathways were activated, as reflected by Smac/DIABLO, HtrA2, and cytochrome c release. Smac/DIABLO and HtrA2 are needed to release the X-linked inhibitor-of- apoptosis protein (XIAP)-mediated block of full caspase 3 maturation. XIAP can effectively block caspase 3 maturation and, intriguingly, is highly expressed in primary but not in transformed keratinocytes. Ectopic XIAP expression in transformed keratinocytes resulted in increased resistance to TRAIL. Our data suggest that breaking of this resistance via proteasome inhibitors, which are potential anticancer drugs, may sensitize certain primary cells to TRAIL-induced apoptosis and could thereby complicate the clinical applicability of a combination of TRAIL receptor agonists with proteasome inhibitors
    Type of Publication: Journal article published
    PubMed ID: 12529384
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...